What is Synairgen?
Synairgen plc operates at the intersection of immunology and respiratory medicine, focusing on the discovery and development of novel drug candidates. The company's primary asset, SNG001, represents a sophisticated application of inhaled interferon beta designed to bolster the immune system's response to severe viral lung infections. By leveraging naturally occurring proteins to regulate immune function, Synairgen addresses a high-unmet need in the treatment of viral pathogens, including coronaviruses. The firm's research pipeline is characterized by a rigorous commitment to clinical validation, positioning it as a key player in the development of prophylactic and therapeutic interventions for respiratory distress. Through its focus on inhaled delivery mechanisms, the company aims to provide targeted, effective solutions that mitigate the systemic impact of viral respiratory diseases.
How much funding has Synairgen raised?
Synairgen has raised a total of $34.5M across 2 funding rounds:
Stock Offering
$12.5M
Other Financing Round
$22M
Stock Issuance/Offering (2004): $12.5M, investors not publicly disclosed
Other Financing Round (2025): $22M led by Tetragon Financial Group
Key Investors in Synairgen
Tetragon Financial Group
Tetragon is a global investment firm focused on alternative assets, providing investors with access to a diversified range of investment opportunities across private equity, credit, real estate, infrastructure, life sciences, digital assets, and other specialized strategies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Synairgen?
With the recent infusion of capital, Synairgen is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic focus will likely center on advancing SNG001 through the necessary regulatory milestones, ensuring that the therapeutic potential of interferon beta is fully realized in clinical settings. As the company transitions into this next phase of growth, the emphasis will remain on scaling its drug discovery infrastructure and strengthening its intellectual property portfolio. Investors and stakeholders are closely monitoring the firm's ability to translate its preclinical successes into tangible patient outcomes, which will be critical for long-term commercial viability in the competitive landscape of respiratory therapeutics. The current funding environment provides the necessary runway to navigate complex clinical trials and pursue potential partnerships that could enhance the reach and efficacy of its proprietary drug candidates.
See full Synairgen company page
